PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 138 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,385,635 | -36.9% | 562,688 | +4.6% | 0.00% | -33.3% |
| Q2 2023 | $14,863,013 | +52.9% | 538,125 | +27.3% | 0.00% | +50.0% |
| Q1 2023 | $9,720,628 | +112.8% | 422,636 | +1.0% | 0.00% | +100.0% |
| Q4 2022 | $4,567,002 | +29.7% | 418,607 | +0.2% | 0.00% | 0.0% |
| Q3 2022 | $3,521,000 | +5.1% | 417,783 | -1.3% | 0.00% | 0.0% |
| Q2 2022 | $3,349,000 | -67.5% | 423,454 | -2.7% | 0.00% | -50.0% |
| Q1 2022 | $10,302,000 | -33.9% | 435,078 | -4.5% | 0.00% | -33.3% |
| Q4 2021 | $15,574,000 | +92.3% | 455,411 | -0.3% | 0.00% | +200.0% |
| Q3 2021 | $8,098,000 | -59.4% | 456,977 | +2.8% | 0.00% | -75.0% |
| Q2 2021 | $19,953,000 | +85.4% | 444,585 | +7.0% | 0.00% | +100.0% |
| Q1 2021 | $10,762,000 | +32.2% | 415,513 | +2.9% | 0.00% | 0.0% |
| Q4 2020 | $8,139,000 | +8.3% | 403,717 | +5.0% | 0.00% | 0.0% |
| Q3 2020 | $7,516,000 | +30.6% | 384,517 | +18.0% | 0.00% | +100.0% |
| Q2 2020 | $5,754,000 | +218.6% | 325,801 | +27.3% | 0.00% | 0.0% |
| Q1 2020 | $1,806,000 | +4.3% | 255,980 | +4.2% | 0.00% | – |
| Q4 2019 | $1,732,000 | -41.5% | 245,676 | -0.4% | 0.00% | -100.0% |
| Q3 2019 | $2,962,000 | +248.1% | 246,609 | +250.6% | 0.00% | – |
| Q2 2019 | $851,000 | +74.0% | 70,340 | +81.0% | 0.00% | – |
| Q1 2019 | $489,000 | +109.0% | 38,863 | +12.2% | 0.00% | – |
| Q4 2018 | $234,000 | -23.0% | 34,624 | +17.2% | 0.00% | – |
| Q3 2018 | $304,000 | +50.5% | 29,540 | -1.8% | 0.00% | – |
| Q2 2018 | $202,000 | -81.5% | 30,092 | -76.3% | 0.00% | – |
| Q1 2018 | $1,092,000 | -58.7% | 127,108 | -0.1% | 0.00% | -100.0% |
| Q4 2017 | $2,647,000 | +53.4% | 127,288 | +30.4% | 0.00% | – |
| Q3 2017 | $1,725,000 | +54.3% | 97,612 | -1.2% | 0.00% | – |
| Q2 2017 | $1,118,000 | +9.6% | 98,825 | +24.0% | 0.00% | – |
| Q1 2017 | $1,020,000 | -43.6% | 79,666 | -3.1% | 0.00% | -100.0% |
| Q4 2016 | $1,807,000 | +325.2% | 82,180 | +308.1% | 0.00% | – |
| Q3 2016 | $425,000 | – | 20,137 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
| COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
| Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
| BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
| RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
| Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
| Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
| 683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
| Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
| Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |